Skip to main content
. 2021 May 21;554:41–48. doi: 10.1016/j.bbrc.2021.03.052

Fig. 4.

Fig. 4

(A) Human B cell tumour lines analysed by immunoblotting for the expression of Pax5 and c-Myb. ALL = Acute lymphocytic leukaemia, BL = Burkitt’s lymphoma, DLBCL = diffuse large B cell lymphoma. (B) Immunoblotting of cell lysates from murine Ba/F3 pro-B cell, pre-B cell, and mature B cell lines for Fbxo7, Pax5 and c-Myb expression. (C) Pax5 chromatin immunoprecipitation of the FBXO7 promoter in Nalm6 cells. Values were then expressed as a percentage relative to input. ∗∗p < 0.01 compared to relevant control IgG levels. n = 2 independent experiments with triplicate qPCR reactions. (D) Graphs of mRNA expression of Nalm6 cells transduced to over-express Pax5 (grey bars) or empty vector (black bars), n = 2. (E) Graph of mRNA expression in Nalm6 cells transduced to express a shRNA construct targeting Pax5 (grey bars), or empty vector (black bars). Pax5 and Fbxo7 mRNA levels were analysed by RT-qPCR, normalised to cyclophilin A levels and expressed relative to empty vector control cells. (F) Immunoblotting of Nalm6 cell lysates transduced with shRNA constructs targeting c-Myb expression, n = 2. (G) Graphs of mRNA expression of Ba/F3 cells transduced to over-express Pax5 (grey bars) or empty vector (black bars), n = 2.